Designing nanobody variants with improved expression and binding against evolving SARS-CoV-2 variants.
The associated work measured expression and binding, not viral neutralization, and therefore represents experimental progress within an ongoing research program.
A GPT-4o PI agent and specialist agents designed 92 nanobody mutants; more than 90% expressed solubly and two improved binding against newer variants in wet-lab tests.